182 related articles for article (PubMed ID: 23945122)
1. Teriparatide (rhPTH) treatment in children with syndromic hypoparathyroidism.
Matarazzo P; Tuli G; Fiore L; Mussa A; Feyles F; Peiretti V; Lala R
J Pediatr Endocrinol Metab; 2014 Jan; 27(1-2):53-9. PubMed ID: 23945122
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism.
Tuli G; Buganza R; Tessaris D; Einaudi S; Matarazzo P; de Sanctis L
Endocrine; 2020 Feb; 67(2):457-465. PubMed ID: 31705387
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide.
Puig-Domingo M; Díaz G; Nicolau J; Fernández C; Rueda S; Halperin I
Eur J Endocrinol; 2008 Nov; 159(5):653-7. PubMed ID: 18703565
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
Mannstadt M; Clarke BL; Vokes T; Brandi ML; Ranganath L; Fraser WD; Lakatos P; Bajnok L; Garceau R; Mosekilde L; Lagast H; Shoback D; Bilezikian JP
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):275-83. PubMed ID: 24622413
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of long term treatment of unresponsive hypoparathyroidism using multipulse subcutaneous infusion of teriparatide.
Díaz-Soto G; Mora-Porta M; Nicolau J; Perea V; Halperin I; Puig-Domingo M
Horm Metab Res; 2012 Sep; 44(9):708-10. PubMed ID: 22473758
[TBL] [Abstract][Full Text] [Related]
7. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.
Clarke BL; Vokes TJ; Bilezikian JP; Shoback DM; Lagast H; Mannstadt M
Endocrine; 2017 Jan; 55(1):273-282. PubMed ID: 27734257
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severe life threatening hypocalcemia with recombinant human teriparatide in patients with postoperative hypoparathyroidism - a case series.
Andrysiak-Mamos E; Żochowska E; Kaźmierczyk-Puchalska A; Popow M; Kaczmarska-Turek D; Pachucki J; Bednarczuk T; Syrenicz A
Endokrynol Pol; 2016; 67(4):403-12. PubMed ID: 27387245
[TBL] [Abstract][Full Text] [Related]
9. Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism.
Marcucci G; Della Pepa G; Brandi ML
Expert Opin Drug Saf; 2017 May; 16(5):617-625. PubMed ID: 28332412
[TBL] [Abstract][Full Text] [Related]
10. [Reduction in requirements of oral calcium and 1-25 dihydroxy vitamin D in patients with post-surgical hypoparathyroidism treated with teriparatide (PTH1-34)].
Gutiérrez-Cerecedo LE; Vergara-López A; Rosas-Barrientos JV; Guillén-González MÁ
Gac Med Mex; 2016; 152(3):322-8. PubMed ID: 27335186
[TBL] [Abstract][Full Text] [Related]
11. Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety.
Rubin MR; Cusano NE; Fan WW; Delgado Y; Zhang C; Costa AG; Cremers S; Dworakowski E; Bilezikian JP
J Clin Endocrinol Metab; 2016 Jul; 101(7):2742-50. PubMed ID: 27144931
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human parathyroid hormone (1-84) replacement therapy in a child with hypoparathyroidism.
Laurer E; Grünberger J; Naidoo U; Lanzersdorfer R; Wimleitner M; Tischlinger K; Högler W
Bone; 2021 Mar; 144():115834. PubMed ID: 33359892
[TBL] [Abstract][Full Text] [Related]
13. AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM.
Lakatos P; Bajnok L; Lagast H; Valkusz Z
Endocr Pract; 2016 May; 22(5):523-32. PubMed ID: 26684150
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human parathyroid hormone (1-84) is effective in CASR-associated hypoparathyroidism.
Hawkes CP; Shulman DI; Levine MA
Eur J Endocrinol; 2020 Dec; 183(6):K13-K21. PubMed ID: 33112267
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism.
Linglart A; Rothenbuhler A; Gueorgieva I; Lucchini P; Silve C; Bougnères P
J Clin Endocrinol Metab; 2011 Nov; 96(11):3308-12. PubMed ID: 21865375
[TBL] [Abstract][Full Text] [Related]
16. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.
Sikjaer T; Amstrup AK; Rolighed L; Kjaer SG; Mosekilde L; Rejnmark L
J Bone Miner Res; 2013 Oct; 28(10):2232-43. PubMed ID: 23649554
[TBL] [Abstract][Full Text] [Related]
17. Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety.
Tay YD; Tabacco G; Cusano NE; Williams J; Omeragic B; Majeed R; Gomez Almonte M; Bilezikian JP; Rubin MR
J Clin Endocrinol Metab; 2019 Nov; 104(11):5601-5610. PubMed ID: 31310310
[TBL] [Abstract][Full Text] [Related]
18. Chronic hypoparathyroidism and treatment with teriparatide.
Marcucci G; Masi L; Cianferotti L; Giusti F; Fossi C; Parri S; Gronchi G; Brandi ML
Endocrine; 2021 Apr; 72(1):249-259. PubMed ID: 33538953
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium.
Winer KK; Ko CW; Reynolds JC; Dowdy K; Keil M; Peterson D; Gerber LH; McGarvey C; Cutler GB
J Clin Endocrinol Metab; 2003 Sep; 88(9):4214-20. PubMed ID: 12970289
[TBL] [Abstract][Full Text] [Related]
20. The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics.
Gittoes N; Rejnmark L; Ing SW; Brandi ML; Björnsdottir S; Hahner S; Hofbauer LC; Houillier P; Khan AA; Levine MA; Mannstadt M; Shoback DM; Vokes TJ; Zhang P; Marelli C; Germak J; Clarke BL
BMC Endocr Disord; 2021 Nov; 21(1):232. PubMed ID: 34801015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
